That gradual dose escalation is not arbitrary
Below is a display of the safety results of the adequate and well-controlled studies of RYBELSUS (referred to below as semaglutide tablets) in adult patients with type 2 diabetes mellitus
Then in an announcement on Tuesday, the drugmaker unveiled that the National Medical Products Administration (NMPA), Chinas top drug regulator, had allowed the injection to be used in weight reduction, making it the first GLP-1 receptor agonist officially available in the country for people who wish to lose weight but for diabetes-unrelated reasons
For some patients, medication may be long-term
Other people start noticing
10.1186/1471-2288-14-135 [DOI] [PMC free article] [PubMed] [Google Scholar] 18.Sterne JAC, Savovi J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials